It is made available under a CC-BY 4.0 International license.

Deuterium metabolic imaging of the human abdomen at clinical field strength

-
- 4 Pascal Wodtke^{1,2}, Mary A McLean^{1,3}, Ines Horvat-Menih^{1,2}, Jonathan R Birchall¹, Maria J Zamora-
- 5 Morales¹, Ashley Grimmer^{1,2}, Elizabeth Latimer¹, Marta Wylot¹, Rolf F Schulte⁴, Ferdia A Gallagher^{1,3}

Author Affiliations

- ¹University of Cambridge, Department of Radiology, Cambridge CB2 000, United Kingdom
- University of Cambridge, Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, United Kingdom
- ³University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, United Kingdom
- 12 ⁴GE HealthCare, Munich, Germany
-

Abstract

Background

- The Warburg effect is a hallmark of cancer and is characterized by increased glucose consumption and
- lactate formation. Deuterium metabolic imaging (DMI) is an emerging non-invasive MRI method for
- probing this metabolic reprogramming in the field of neuroimaging. Here we show the feasibility of
- the technique for abdominal imaging using a routine 3 T MRI system, which has previously presented
- significant technical challenges.

Purpose

- This study aimed to translate abdominal DMI to clinical field strength by optimizing the
- 24 radiofrequency coil setup, the administered dose of deuterium $({}^{2}H)$ -labelled glucose, and the data
- processing pipeline for quantitative characterization of DMI signals over time in the kidney and liver,
- establishing a basis for routine clinical studies in the future.

Materials and Methods

- 28 Five healthy volunteers were recruited and imaged on 2 or 3 occasions, with different ${}^{2}H$ -glucose
- 29 doses (totalling 13 DMI scan sessions). DMI was performed at 3 T using a flexible 20×30 cm² ²H-
- tuned transmit-receive surface coil. We have defined three novel quantitative parameters as metrics of
- metabolism and compared these between doses and organs.

Results

- The careful positioning of a dedicated surface coil minimized unwanted gastric signals while
- maintaining excellent hepatic and renal measurements. The timecourses derived from the liver and
- kidney were reproducible and comparable across different doses, with a trend towards lower **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

It is made available under a CC-BY 4.0 International license.

2

- 36 quantitative measurements with decreasing dose. An increase in the 2 H-water signal over time
- 37 particularly in the liver, could be used as an indirect measure of metabolism.

38 **Conclusion**

- 39 DMI of the human abdomen is feasible using a routine MRI system and the metabolism measured in
- 40 the kidney and liver can serve as a reference for future clinical studies. The ${}^{2}H$ -glucose dose can be
- 41 reduced from 0.75 to 0.25 g/kg to minimize gastric signal without substantially affecting the
- 42 reliability of organ quantification.

It is made available under a CC-BY 4.0 International license.

Aerobic glycolysis, or the Warburg effect, occurs in a wide range of cancers and describes the increase

Introduction

48 in glucose breakdown which occurs even in the presence of abundant oxygen¹. This effect is characterized by upregulated glucose consumption and the formation of downstream lactate that accumulates in the extracellular space, creating a hostile acidic extracellular tumor environment. A number of novel metabolic MRI methods have recently emerged to exploit this metabolism which have the potential for identifying more aggressive tumor subtypes and for assessing early metabolic 53 response to treatments²⁻⁵. In 2018, deuterium metabolic imaging (DMI) emerged as one of these non-invasive methods to assess 55 glycolytic metabolism in the brain and cerebral tumors⁶. Unlike conventional proton $({}^{1}H)$ MRI, 56 deuterium (2 H) is found at very low natural abundance ($~0.01\%$), and therefore deuterium spectra contain almost no background signal apart from the large peak arising from naturally-abundant, and 58 partially-deuterated water $(^{2}H$ -water) signal, with some smaller deuterated peaks from adipose tissue. DMI exploits this low background signal through the administration of exogenous ${}^{2}H$ -labelled 60 molecules such as ²H-glucose $([6, 6^{\text{-2}}H_2]$ glucose)⁷⁻¹¹. This labelled glucose is very safe¹² and can be conveniently administered orally, thereby facilitating clinical use of the technique (Fig. 1a). Following 62 absorption in the gastrointestinal tract, ${}^{2}H$ -glucose metabolism can be followed spatially and 63 temporally using deuterium magnetic resonance spectroscopic imaging $(^{2}H-MRSI)^{6,9}$. Despite having great potential for assessing glycolysis, DMI has faced several challenges in its 65 translation into clinical field strength^{7,13}. Whilst DMI has recently been translated to 3 T in the brain^{9,14}, DMI outside of the brain suffers from additional challenges including: increased tissue inhomogeneity, motion, poor shimming, prominent gastric signal from the oral probe, and overlap between the naturally-abundant lipid peak and the tumor 2 H-lactate signal, all of which reduce 69 spectral quality. For these reasons, abdominal DMI has only been conducted at 7 T to date^{8,10}. In this study, we have addressed these challenges and conducted abdominal DMI in healthy volunteers at 3 T. The oral ²H-glucose dose has been varied to explore the optimal dose required for clinical imaging, to reduce both the cost and the gastric signal arising from the oral ingestion of the probe, 73 without affecting the desired signal from the abdominal organs¹⁵. We demonstrate the feasibility of quantitative abdominal DMI of the liver and kidney at clinical field strength and present a robust 75 pipeline for assessing 2 H-glucose spectra for future clinical use including novel metrics of metabolism.

It is made available under a CC-BY 4.0 International license.

4

78 **Table 1 | Demographics.** Details about the individual volunteers and the dose received at each visit.

79

- 81 **Figure 1 | Study schema and experimental procedure. (a)** DMI as a technique. A solution
- 82 containing ²H-glucose is prepared and orally administered, followed by spectroscopic imaging.
- 83 **(b)** n = 5 volunteers were imaged on two $(n = 2)$ or three $(n = 3)$ different days, totalling 13 imaging
- 84 sessions. At each visit, the volunteers received one of three dose regimens of the ²H-glucose.
- 85

It is made available under a CC-BY 4.0 International license.

Materials and Methods

Study Design

The study was approved by a local research ethics committee (23/YH/0127) and all five recruited

healthy volunteers (4 male, 1 female, age range = 20-30, Table 1) gave informed consent in writing.

To assess the effect of dose reduction, the volunteers underwent up to three DMI studies on different

93 days, receiving different doses of ²H-glucose (Cambridge Isotope Laboratories Inc., Tewksbury, MA),

dissolved in water for injection (B. Braun, Melsungen, Germany), as shown in Table 1. The three dose

regimens chosen for this study include the current standard dose given to volunteers and patients in

96 previously published studies^{9,11} ("high"), as well as a dose reduction of one-third ("medium") and

97 two-thirds ("low") of the standard dose. The "high" dose corresponds to 0.75 g/kg , with a maximum

administration of 60 g. All five volunteers received the high and the low dose, while three volunteers

99 also received the medium dose, totalling $n = 13$ DMI sessions. The volunteers were fasted for 6 h pre-

scan. Prior to, and immediately after each exam, blood pressure, heart rate, blood oxygen saturation,

and blood glucose level were recorded (Fig. S1).

²H-MR Spectroscopy and Imaging

 The volunteers were positioned supine in the MRI (3 T Premier, GE Healthcare, Chicago, IL) head- first. A flexible 20x30 cm² ²H-transmit-receive surface coil (RAPID Biomedical, Rimpar, Germany) was wrapped around the right side of the abdomen, and fixed via Velcro straps, with the center of the 108 coil positioned between the liver and kidney. An axial T_1 -weighted volume (LAVA-flex) was acquired for co-registration using the built-in body coil. Subsequently, a series of Hamming-filtered density-110 weighted ²H-MRSI (real matrix size = $10x10x10$, 1678 interleaves, FOV = 40 cm, FA = 60° , TE = 0.7 111 ms, $TR = 250$ ms) were acquired for ≤ 90 min, interleaved between acquisitions, by the collection of 112 unlocalized ²H spectra (TE = 0.7 ms, TR = 600 ms, FA = 90° , 64 averages).

Data Processing and Analysis

 Spectra were zero-filled by a factor of two in all three spatial dimensions and fitted automatically using 117 a customised version of OXSA-AMARES^{16,17} with an SNR threshold of five. For display in Fig. 5, spatial interpolation by a factor of 12.8 in plane and a factor of 2 in the z-dimension was conducted. 119 Voxels were manually assigned to the respective organs using an overlay of the summed ²H-signal and

It is made available under a CC-BY 4.0 International license.

6

120 the axial anatomical LAVA-flex ¹H localizer (FOV = 48 cm, FA = 12° , TEs = $1.1/2.2$ ms, TR = 3.96

121 ms), as seen in Fig. 3. For liver, kidney, and duodenum, the prior knowledge of the fitting routine

122 included three peaks: 2 H-water, 2 H-glucose, and 2 H-lipid+lactate, as those commonly expected for DMI

123 studies in the abdomen¹⁰. For the stomach, the prior knowledge was set to detect only one peak, assumed

124 to be ²H-glucose in the absence of metabolism. Peak amplitudes, as fitted by OXSA-AMARES, were

125 used to calculate the GGW and LLW (equation 1 and 2) ratio for every organ and timepoint using

126 MATLAB (MathWorks, Natick, MA). The GGW and LLW ratio represent the respective normalization 127 of ²H-glucose and ²H-lipid+lactate signals against the naturally abundant ²H-water peak to compare 128 across scans as defined in equations 1 and 2:

129
$$
GGW(t) = \frac{gluc(t)}{gluc(t) + wat(t)}
$$
 equation 1

130
$$
LLW(t) = \frac{liplac(t)}{liplac(t) + wat(t)}
$$
 equation 2

131 with gluc(t), liplac(t) and wat(t) representing the ²H-glucose, ²H-lipid+lactate (whose peaks overlap) 132 and ²H-water signals at the respective timepoints. The GGW provides a normalized metric of ²H-glucose 133 uptake, which is comparable across participants as a potentially useful clinical measurement. LLW is a 134 similar comparative metric, which at baseline is dominated by the lipid signal and any increase over 135 time corresponds to lactate formation in the organ of interest. For quantitative analysis of the 136 timecourses, GGW_{max} , GGW_{AUC} , and GGW_{mean} plateau were calculated. GGW_{max} was determined by 137 taking the maximum GGW value in each organ timecourse. For GGW_{AUC}, the GGW value of each 138 timepoint t_n was multiplied by the time difference $t_n - t_{n-1}$ between the previous timepoint in minutes 139 (equation 3). The separate AUC(t) values were then summed until $t = 74$ min, which was a common 140 timepoint across volunteers and exams, to make the GGW_{AUC} comparable across volunteers and across 141 scans:

$$
142 \\
$$

142
$$
GGW_{AUC}(x) = \sum_{n=1}^{x} GGW(t_n) \cdot (t_n - t_{n-1});
$$
 with $t_x = 74$ min equation 3

143 GGW_{mean plateau} was determined by taking the mean GGW of all timepoints after signal plateauing. The 144 plateau time was determined to be $t = 30$ min for liver, and $t = 40$ min for kidney, broadly aligning with 145 previously published studies¹⁰. For unlocalized spectroscopy, the GGW_{mean plateau} was replaced by 146 GGW_{mean} over the whole timecourse, since the detection of signal build-up, and subsequent plateauing, 147 was not possible for all scans, depending on the contribution of the stomach to the overall detected 148 signal. For statistical analysis, Analysis of Variance (ANOVA) was performed in GraphPad Prism 149 (GraphPad Software, Boston, MA), followed by Tukey's Honestly Significant Difference (HSD) test as 150 post-hoc analysis.

It is made available under a CC-BY 4.0 International license.

7

¹⁵² **Results**

153 **Unlocalized Spectroscopy**

- 155 Unlocalized spectra showed good SNR (> 5) for all three dose regimens, with the ²H-water (4.7 ppm)
- 156 and ²H-glucose (3.7 ppm) peaks being clearly resolved at clinical field strength (Fig. 2a-c).
- 157 Interestingly, the GGW ratio derived from these unlocalized spectra showed ${}^{2}H$ -glucose build-up
- 158 steadily over time in some volunteers, while appearing early in others (Fig. 2d). This is because,
- 159 depending on the coil positioning, the stomach and duodenum were detectable in some cases,
- 160 resulting in an early and high ²H-glucose signal in some cases. The low dose regimen exhibited a
- 161 lower GGW across all metrics (Fig. 2e; $GGW_{max} = 0.44 \pm 0.03$; $GGW_{mean} = 0.35 \pm 0.05$; $GGW_{AUC} =$
- 162 24.1 \pm 5.0; n = 4) compared to the medium (GGW_{max} = 0.55 \pm 0.07, p = 0.0902; GGW_{mean} = 0.48 \pm
- 163 0.05, p = 0.0193; GGW_{AUC} = 28.8 \pm 2.7; p = 0.5097, n = 3) and the high doses (GGW_{max} = 0.57 \pm
- 164 0.07, p = 0.0247; GGW_{mean} = 0.47 \pm 0.05, p = 0.0148; GGW_{AUC} = 33.8 \pm 6.4, p = 0.0560; n = 5).
- 165 Statistically significant results are indicated in Fig. 2e. Notably, there was no significant difference in
- 166 quantitative values between the medium and the high dose across all the metrics. The dynamics of the
- 167 fitted ²H-glucose signal amplitude showed a signal build-up over 60 min in most cases (Fig. 2f). An
- 168 increase in the ²H-water signal over time could be observed in all cases, ranging from 10-56% when
- 169 comparing the last timepoint with the first in each case (Fig. 2g-h, Fig. S2).

8 It is made available under a CC-BY 4.0 International license.

170

171 **Figure 2 | Dynamic unlocalized spectroscopy acquired from the healthy abdomen after oral administration of ²H-glucose. (a-c)** Spectral timecourses demonstrating ²H-water and ²H-glucose 173 peaks from a single volunteer $(\#3)$ after receiving the following ²H-glucose doses: (a) high; (b) 174 medium; (c) low. **(d)** Timecourse of GGW (see methods) for each volunteer at each visit. **(e)** The three 175 different quantitative measures we have introduced to evaluate ${}^{2}H$ -glucose signal over time (see 176 methods). **(f)** The total ²H-glucose signal initially increases with respect to the first timepoint in all 177 volunteers and starts to decline after \sim 50-60 minutes. **(g)** The ²H-water grows moderately over time in 178 all volunteers, hinting suggesting the production of water through metabolism. **(h)** First (start) vs. last 179 (end) timepoint of the data shown in (g), to demonstrate that all volunteers exhibit a growth in the ${}^{2}H$ -180 water signal, thus suggesting a consistent effect.

181

182 **Imaging**

- 185 13; Fig. 3), and in the stomach and duodenum in most cases ($n = 10$ and 11 respectively). Only ²H-
- 186 glucose could be detected in the stomach, while the duodenum exhibited a small but detectable ${}^{2}H$ -

It is made available under a CC-BY 4.0 International license.

9

- 187 water peak. The kidney exhibited a small lipid peak which was probably secondary to partial volume
- 188 effects from the surrounding visceral fat.
- 189 The timecourses for the kidney (Fig. 4a) and the liver (Fig. 4b) showed a build-up in the GGW ratio,
- 190 with the liver plateauing earlier at \sim 30 min, compared to the kidney at \sim 40 min. GGW signal in the
- 191 duodenum remained high throughout the whole timecourse (Fig. 4c). The raw or non-normalized 2 H-
- 192 glucose signal was assessed in the stomach due to the low $2H$ -water signal, which showed a decrease
- 193 over time in all cases as gastric emptying occurred (Fig. 4d).

194

Figure 3 | Representative images derived from spatially resolved spectroscopy. The summed ²H 196 signal is shown as a colorscale image with single-voxel spectra from each organ (volunteer 5, $t = 33$) 197 min after receiving the high (gold) and the medium (blue) doses. Stomach and duodenal ROIs are 198 dominated by the ²H-glucose signal, whereas kidney and liver exhibit a prominent ²H-water peak as 199 well as a small lipid peak in the kidney. The boxes in the images indicate non-interpolated voxel sizes.

It is made available under a CC-BY 4.0 International license.

10

201 **Comparison between the liver and kidney, and between doses**

202

203 Across all three dose regimens and all three quantitative metrics, the liver exhibited a significantly

- 204 higher ²H-glucose uptake than the kidney (Fig. 4e-h, p-values for $GGW_{max}/GGW_{mean}/GGW_{AUC}$:
- 205 0.0097/0.0032/0.0044). Furthermore, all three values increased with dose in both the liver and kidney.
- 206 Notably, this trend was statistically significant between the low dose and the other two doses, but not
- 207 between the high and the medium dose. Relevant p-values are shown in Figure S3. Example imaging
- 208 timecourses from volunteer 5 for all three doses are displayed in Figure 5.
- 209

²H-lipid content and 210 **²H-lactate formation**

211

212 The ²H-lactate signal appears at a similar chemical shift as the ²H-lipid signal (both at ~1.3 ppm)¹⁸, 213 and as lipid is particularly abundant in the abdomen^{19,20} this presents a challenge for the accurate 214 quantification of 2 H-lactate. Hence, it is more important to characterize the naturally abundant lipid 215 signal on abdominal DMI, compared to the brain where the majority of previous DMI research has 216 been undertaken.

217 A small ²H-lipid peak was identified in voxels overlying the kidney, and to a lesser extent the liver,

218 which was likely due to partial volume effects from the visceral fat surrounding these organs (Fig. 3).

219 The LLW ratio was calculated and the respective timecourses for both organs are displayed in Fig.

220 4i/j. The lipid content was higher in the kidney (mean across all volunteers and timepoints: 0.27 ± 1

221 0.10) compared to the liver (0.21 ± 0.08) .

- 222 Lactate plays an important role in many pathological processes and therefore it is key to quantify the
- 223 background ²H-lactate signal derived from normal organs after oral administration of ²H-glucose as a
- 224 reference. Fig. 6a shows the normalized ²H-lipid+lactate signal for the three volunteers that were
- 225 administered all three doses. A direct comparison of the last timepoint compared to the first for all
- 226 volunteers can be seen in Fig. 6b-c. In the liver, the ${}^{2}H$ -lipid+lactate signal increased in 12/13
- 227 examinations, with an average increase of $38.5 \pm 24.2\%$ showing that the healthy liver exhibits
- 228 detectable ²H-lactate 60-80 min after administering oral ²H-glucose. In contrast, the ²H-lipid+lactate
- 229 signal increased in only 8/13 examinations in the kidney, with an average increase of only $5.0 \pm 17\%$,
- 230 suggesting very little lactate formation in this timescale.

It is made available under a CC-BY 4.0 International license.

11

 h

liver lipid timecourse

It is made available under a CC-BY 4.0 International license.

12

Figure 4 Quantitative evaluation of imaging data. (a-c) GGW timecourses for ²H-glucose signal 233 in the kidney (a), liver (b) and duodenum (c). **(d)** ²H-glucose signal in the stomach over time shows a 234 decrease likely to correspond to gastric emptying. **(e-g)** Quantitative measures of GGW_{AUC} (e), 235 GGW_{mean plateau} (f) and $\overline{GGW}_{max}(g)$ exhibit dose dependence in the liver and kidney, whereas they 236 remain elevated in the duodenum regardless of dose. **(h)** Summarized quantitative values displayed in 237 (e-g). (i,j) ²H-lipid signal, as evaluated by the LLW parameter (see methods) over time. The kidney (i) 238 shows a generally higher LLW than the liver (j), indicating a higher lipid content inside the imaged

239 kidney voxels, which is likely to arise from the surrounding visceral fat.

240

241 **²H-water signal increase as an indirect measure of metabolism**

242

243 The unlocalized spectroscopy showed an increase in ²H-water signal over time (Fig. 2g-h), which has

- 244 been reported in previous preclinical and clinical studies^{9,10,21}. Spectroscopic imaging was
- 245 subsequently used to localize this signal increase; Fig. 6d shows the normalized 2 H-water signal for
- 246 the three volunteers that were administered all three doses. A direct comparison of the last timepoint
- 247 compared to the first for all volunteers can be seen in Figures 6e-f. In the kidney, the 2 H-water signal
- 248 increased over time in 10/13 examinations, with an average increase of 10.3 ± 12.8 %. In the liver, the

249 ²H-water signal increased in all 13 examinations, with an average increase of 17.6 \pm 9.7%. Hence, the

- liver is likely driving the 250 ²H-water signal increase in the unlocalized spectroscopy data. Indeed, the
- 251 three examinations with the largest ²H-water signal increases in the unlocalized spectra were the same
- 252 three examinations that exhibited the largest ²H-water signal increase in the liver imaging data. This
- 253 observation further confirms the conclusion, that the liver is causing the dominant part of the ²H-water
- 254 signal increase in the unlocalized spectra.

It is made available under a CC-BY 4.0 International license.

13

Figure 5 | Imaging timecourses for 256 **²H-glucose for all three dose regimens administered to**

257 volunteer 5. (a) A slice containing both the liver and stomach showing declining ²H-glucose signal in

258 the stomach and increasing signal in the liver. **(b)** A slice containing both the kidney and the duodenum: the kidney shows a build-up of ${}^{2}H$ -glucose, whereas the duodenum signal shows

duodenum: the kidney shows a build-up of ${}^{2}H$ -glucose, whereas the duodenum signal shows little

260 variation in signal intensity over time. Timecourses of the ²H-water signal, as well as the summed ²H-

261 signal can be viewed in the supplementary information (Fig. S4, S5).

262

It is made available under a CC-BY 4.0 International license.

14

Figure 6 | ²H-water and 264 **²H-lipid+lactate signal derived from individual volunteers over time, extracted from the imaging data. (a)** ²H-lipid+lactate signal from the three volunteers that 266 underwent all three imaging sessions. Unlike the kidney, the liver showed a trend towards an 267 increasing signal over time, up to x2.5 the initial value. **(b,c)** Comparison of the first and last 268 time points from all the volunteers reveals a trend towards increasing $2H$ -lipid+lactate signal in the 269 liver (c), whereas the kidney (b) shows no trend across volunteers. The liver data suggests the hepatic 270 formation of ²H-lactate from ²H-glucose in the timecourse of the experiment. **(d)** Comparative ²H-271 water signal of the same three volunteers. The liver shows a clear and consistent increase in 2 H-water 272 signal over time. **(e,f)** Comparison of the first and last timepoints from all the volunteers reveals a

It is made available under a CC-BY 4.0 International license.

15

273 trend towards increasing ${}^{2}H$ -water signal in both kidney (e) and liver (f) over time. In the case of the 274 liver, the 2 H-water signal increased in all volunteers.

²⁷⁵ **Discussion**

276

277 Deuterium metabolic imaging is an emerging method for probing tissue metabolism with potential 278 applications in a wide range of diseases given the importance of glucose utilization in both health and 279 disease. Here we translate the technique to the abdomen at clinical field strength, showing its 280 feasibility for assessing hepatic and renal metabolism. We also optimize the dose of oral ${}^{2}H$ -glucose 281 for clinical use and present metrics to quantitatively evaluate its uptake and metabolism in tissues. 282 The signal from ²H-glucose was evaluated up to 90 min after oral administration and could be used to 283 evaluate accumulation and absorption in the stomach and duodenum. Importantly, the use of a surface

284 coil in combination with its positioning around the right side of the abdomen was used to minimize

285 unwanted gastric signal when imaging the liver and kidney. The liver generally exhibited a higher 2 H-

286 glucose signal compared to the kidney, rapid plateauing of the signal, more reproducible time curves,

287 and a lower lipid signal, therefore making it a promising organ to be assessed using DMI.

288 The increase in ²H-water signal over time is likely to arise from water derived from glucose

289 metabolism^{22,23}. The liver showed a higher ²H-glucose uptake than the kidney, as well as the formation

290 of a small ²H-lipid+lactate signal, in keeping with increased hepatic metabolism. A confounder when

291 analyzing DMI data is that the long timecourse for acquisition allows for metabolites from other

292 organs to be washed into the organ under assessment so the measured signal may not be due to

293 metabolism in the organ under investigation.

294 The doses of ²H-glucose used in DMI range from 60-75 $g^{8-11,24}$, with 75 g being the standard dose for

295 a clinical glucose tolerance test²⁵. The blood glucose is transiently increased during these dose

296 regimens, and we show that this could be avoided by lowering the dose to \sim 20 g, allowing steady state

297 metabolism to be probed without a substantial loss in signal (Fig. S1). This reduces the cost of DMI as

298 well as the risk of unwanted gastric signal contaminating the quantification from other organs.

299 As an emerging technique, the best approaches for quantitative assessment and kinetic modelling of

300 DMI are yet to be determined. The challenges are similar to other time-resolved metabolic imaging

301 methods, such as those found in the analysis of positron emission tomography (PET)²⁶ and

 1302 hyperpolarized ¹³C-MRI data^{27,28}. However, DMI also presents some problems unique to the technique

303 and here we have proposed three novel quantitative biomarkers for assessment of this dynamic data:

 304 GGW_{AUC}, GGW_{mean plateau}, and GGW_{max}. The results show that the hepatic and renal measurements are

305 influenced by the administered dose but do not scale with it, suggesting a rate limiting element in

It is made available under a CC-BY 4.0 International license.

 delivery and metabolism. It is interesting to note that, despite the range of doses given across different volunteers, the duodenal measurements are remarkably constant over time and between individuals.

308 The increase in the ²H-lipid+lactate signal observed in the liver is likely to be from lactate formation

309 as lipogenesis occurs on a slower timescale²⁹. The lipid signal demonstrates a low SNR and has a

310 broader linewidth compared to the ${}^{2}H$ -water and ${}^{2}H$ -glucose and may be overestimated while fitting

with the automated approach here, which calculates a peak area.

One limitation of this study is the small cohort size; extending this study into larger cohorts and

undertaking formal repeatability and reproducibility studies in a multisite setting will be important for

- future research in this field. Normalized plots have been referenced to the first timepoint of the same
- exam and this reference timepoint differed across examinations. It would be advantageous to
- 316 reference the ²H-water and ²H-lipid signals against the naturally abundant measurements at baseline,

but as the participants were repositioned after drinking in the upright position, the exact placement of

the coil could change, potentially resulting in misregistration. Future studies could overcome this by

319 maintaining the participant on the scanner with the coil in position and administering the 2 H-glucose

320 using a straw⁸, allowing the natural abundance scan to be directly compared to the post-administration

- images. Intravenous injection of ²H-glucose could also be considered in the future, bypassing
- gastrointestinal uptake, which would reduce the required dose further and lead to more rapid substrate
- delivery. However, this may result in a transient supraphysiological dose of glucose which could alter

tissue metabolism.

Conclusion

In conclusion, these data demonstrate the feasibility of quantitative DMI in the kidney and liver at

clinical field strength, without signal interference by the stomach. Furthermore, we show that the

administered dose can be significantly reduced, reducing the costs of a DMI scan and the otherwise

dominant gastric signal, which are important considerations for future clinical use. Additionally, we

- introduced new methodology to assess glucose uptake and metabolism, which could be used to
- quantify tissue metabolism in disease settings.

It is made available under a CC-BY 4.0 International license.

Acknowledgements

- PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support
- from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by
- Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre,
- Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views
- expressed are those of the authors and not necessarily those of the NIHR or the Department of Health
- and Social Care. The authors also acknowledge support from the National Cancer Imaging
- Translational Accelerator (NCITA) and The Mark Foundation Institute for Integrative Cancer
- Medicine (MFICM) at the University of Cambridge.
-

References

-
- 1. Warburg, O. ueber den Stoffwechsel der Carcinomzelle. *Naturwissenschaften* **12**, 1131–1137 (1924) doi: 10.1007/BF01504608.
- 2. Tekade, R. K. & Sun, X. The Warburg effect and glucose-derived cancer theranostics. *Drug Discov. Today* **22**, 1637–1653 (2017) doi: 10.1016/j.drudis.2017.08.003.
- 3. Hesketh, R. L. & Brindle, K. M. Magnetic resonance imaging of cancer metabolism with
- hyperpolarized ¹³ C-labeled cell metabolites. *Curr. Opin. Chem. Biol.* **45**, 187–194 (2018) doi:
- 10.1016/j.cbpa.2018.03.004.
- 4. Kreis, F. *et al.* Measuring Tumor Glycolytic Flux in Vivo by Using Fast Deuterium MRI.
- *Radiology* **294**, 289–296 (2020) doi: 10.1148/radiol.2019191242.
- 5. Low, J. C. M. *et al.* Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes
- and detects early response to chemoradiotherapy. *Cancer Res.* (2024) doi:10.1158/0008-
- 5472.CAN-23-2552 doi: 10.1158/0008-5472.CAN-23-2552.
- 6. De Feyter, H. M. *et al.* Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of
- metabolism in vivo. *Sci. Adv.* **4**, eaat7314 (2018) doi: 10.1126/sciadv.aat7314.

It is made available under a CC-BY 4.0 International license.

7. De Feyter, H. M. & De Graaf, R. A. Deuterium metabolic imaging – Back to the future. *J. Magn.*

Reson. **326**, 106932 (2021) doi: 10.1016/j.jmr.2021.106932.

- 8. Poli, S. *et al.* Interleaved trinuclear MRS for single‐session investigation of carbohydrate and
- lipid metabolism in human liver at 7T. *NMR Biomed.* **37**, e5123 (2024) doi: 10.1002/nbm.5123.
- 9. Kaggie, J. D. *et al.* Deuterium metabolic imaging and hyperpolarized 13C-MRI of the normal
- human brain at clinical field strength reveals differential cerebral metabolism. *NeuroImage* **257**,
- 119284 (2022) doi: 10.1016/j.neuroimage.2022.119284.
- 10. Gursan, A. *et al.* Deuterium body array for the simultaneous measurement of hepatic and renal
- glucose metabolism and gastric emptying with dynamic 3D deuterium metabolic imaging at 7 T.

NMR Biomed. **36**, e4926 (2023) doi: 10.1002/nbm.4926.

- 11. Khan, A. S. *et al.* Deuterium Metabolic Imaging of Alzheimer Disease at 3-T Magnetic Field
- Strength: A Pilot Case-Control Study. *Radiology* **312**, e232407 (2024) doi:
- 10.1148/radiol.232407.
- 12. Jones, P. J. H. & Leatherdale, S. T. Stable isotopes in clinical research: safety reaffirmed. *Clin. Sci.* **80**, 277–280 (1991) doi: 10.1042/cs0800277.
- 13. Graaf, R. A. *et al.* On the magnetic field dependence of deuterium metabolic imaging. *NMR Biomed.* **33**, e4235 (2020) doi: 10.1002/nbm.4235.
- 14. Adamson, P. M. *et al.* Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T. *Magn. Reson. Med.* **91**, 39–50 (2024) doi: 10.1002/mrm.29830.
- 15. Ahmadian, N. *et al.* Human Brain Deuterium Metabolic Imaging at 7 T : Impact of Different [6,6′‐ ²H2]Glucose Doses. *J. Magn. Reson. Imaging* jmri.29532 (2024) doi:10.1002/jmri.29532
- doi: 10.1002/jmri.29532.
- 16. Purvis, L. A. B. *et al.* OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. *PLOS ONE* **12**, e0185356 (2017) doi: 10.1371/journal.pone.0185356.
- 17. Vanhamme, L., van den Boogaart, A. & Van Huffel, S. Improved Method for Accurate and
- Efficient Quantification of MRS Data with Use of Prior Knowledge. *J. Magn. Reson.* **129**, 35–43
- (1997) doi: 10.1006/jmre.1997.1244.

- 18. Fan, T. W.-M. Metabolite profiling by one- and two-dimensional NMR analysis of complex
- mixtures. *Prog. Nucl. Magn. Reson. Spectrosc.* **28**, 161–219 (1996) doi: 10.1016/0079-
- 6565(95)01017-3.
- 19. Htun, K. T. *et al.* Advanced Molecular Imaging (MRI/MRS/1H NMR) for Metabolic Information
- in Young Adults with Health Risk Obesity. *Life* **11**, 1035 (2021) doi: 10.3390/life11101035.
- 20. Tkáč, I. *et al.* In vivo ¹ H NMR spectroscopy of the human brain at 7 T. *Magn. Reson. Med.* **46**,
- 451–456 (2001) doi: 10.1002/mrm.1213.
- 21. Montrazi, E. T., Sasson, K., Agemy, L., Scherz, A. & Frydman, L. Molecular imaging of tumor
- metabolism: Insight from pyruvate- and glucose-based deuterium MRI studies. *Sci. Adv.* **10**,
- eadm8600 (2024) doi: 10.1126/sciadv.adm8600.
- 22. Mellanby, K. Metabolic Water and Desiccation. *Nature* **150**, 21–21 (1942) doi:
- 10.1038/150021a0.
- 23. Sawka, M. N., Cheuvront, S. N. & Carter, R. Human Water Needs. *Nutr. Rev.* **63**, S30–S39 (2005) doi: 10.1111/j.1753-4887.2005.tb00152.x.
- 24. Bøgh, N., Vaeggemose, M., Schulte, R. F., Hansen, E. S. S. & Laustsen, C. Repeatability of
- deuterium metabolic imaging of healthy volunteers at 3 T. *Eur. Radiol. Exp.* **8**, 44 (2024) doi:
- 10.1186/s41747-024-00426-4.
- 25. Jagannathan, R. *et al.* The Oral Glucose Tolerance Test: 100 Years Later. *Diabetes Metab. Syndr. Obes. Targets Ther.* **Volume 13**, 3787–3805 (2020) doi: 10.2147/DMSO.S246062.
- 26. Graham, M. M., Peterson, L. M. & Hayward, R. M. Comparison of simplified quantitative
- analyses of FDG uptake. *Nucl. Med. Biol.* **27**, 647–655 (2000) doi: 10.1016/S0969-
- 8051(00)00143-8.
- 27. Larson, P. E. Z. *et al.* Investigation of analysis methods for hyperpolarized 13C‐pyruvate
- metabolic MRI in prostate cancer patients. *NMR Biomed.* **31**, (2018) doi: 10.1002/nbm.3997.
- 28. Daniels, C. J. *et al.* A comparison of quantitative methods for clinical imaging with
- hyperpolarized ¹³ C‐pyruvate. *NMR Biomed.* **29**, 387–399 (2016) doi: 10.1002/nbm.3468.

It is made available under a CC-BY 4.0 International license.

- 29. Schwarz, J.-M., Clearfield, M. & Mulligan, K. Conversion of Sugar to Fat: Is Hepatic de Novo
- Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases? *J. Osteopath.*
- *Med.* **117**, 520–527 (2017) doi: 10.7556/jaoa.2017.102.